CA-VISA-INC.
Kicking off Women’s History Month, Visa (NYSE:V) today announced two new partnerships bolstering the company’s commitment to women’s economic empowerment. Hand In Hand International and IFundWomen will join Visa to help provide both educational resources and funding for women entrepreneurs around the globe to help them build and grow their businesses. The global rate of female entrepreneurship has been increasing more quickly than that of male entrepreneurs1 , with more than 250 million women around the world engaged in entrepreneurship2 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005388/en/
“Women power economies around the world and increasingly are a driving force in the creation of new businesses,” said Al Kelly, chief executive officer and chairman, Visa. “Visa is committed to using the full power of our network, brand and financial resources to put a spotlight on this growing economic force and help female entrepreneurs achieve their dreams.”
About the Partnerships:
- IFundWomen : IFundWomen is a funding and education platform that provides access to capital through grants and crowdfunding, expert business coaching and a network of women business owners. Visa’s new global partnership with IFundWomen is specifically designed to help entrepreneurs secure the funding they need through a series of grant contests. To find out more and apply for a grant, entrepreneurs can visit IFundWomen.com/Visa .
- Hand in Hand International: As part of the company’s mission to enable individuals, businesses and economies to thrive, Visa is launching a $2.4 million, three-year partnership with Hand in Hand International, a global non-profit organization that focuses on developing economies in Africa, South Asia and the Middle East. Visa’s partnership with Hand in Hand International will focus on providing business education and broadened financial services access to 10,000 micro businesses in Kenya – at least 75% of which are owned by women. The partnership will further women’s economic empowerment, which has a multiplier effect3 , boosting economic growth and leading to greater development outcomes.
In conjunction with the partnerships, Visa today unveiled initial findings from the second annual “State of Female Entrepreneurship” report4 . The annual study seeks to understand the goals, aspirations and challenges facing women business owners today. Key findings included that funding remains a top challenge: 79% of women entrepreneurs in the United States feel more empowered now than they did five years ago, yet 66% report difficulty in obtaining the funding they need.
“In an increasingly digital world, businesses need to constantly adapt to shifting consumer preferences. But keeping up is challenging, especially for a small business. The women entrepreneurs I have met echo a need for more access to capital to fund, run and grow their businesses,“ said Suzan Kereere, global head of merchant sales and acquiring, Visa. “We are excited to help level the playing field through more access to tools and grants this year, and will continue to champion women in all facets of life in the pursuit of an inclusive digital society.”
Visa has demonstrated a longstanding commitment to empower women through partnerships, programs and sponsorships. The company’s more recent efforts include:
-
Women in Business:
- Female Founder Collective: Visa has entered its second year of partnership with Rebecca Minkoff’s Female Founder Collective . To kickoff, Visa will host a workshop at Female Founders Day , where a diverse mix of lending and digital payment experts will discuss strategies small business can use for loans and capital.
- Women’s World Banking: In 2017, the Visa Foundation made their inaugural grant of $20 million to Women’s World Banking to help women-led micro and small business owners increase access to capital and to help grow their businesses. The program is on track to reach 1 million women by the end of the year.
- She’s Next, Empowered by Visa: In 2019, Visa launched its women-owned small business initiative, She’s Next, Empowered by Visa , with workshops in New York, Atlanta, Toronto and Cape Town at the World Economic Forum in South Africa. She’s Next leverages Visa’s brand and network to empower women entrepreneurs with tools to build their businesses, ultimately creating a ripple effect throughout their communities.
-
Women in Sport:
- The SheBelieves Cup: As the sponsor of the SheBelieves Cup, Visa will present the first-ever MVP trophy to the most inspiring and empowering athlete on the field during the tournament, selected by a committee of former female footballers. Visa will also host a Practical Money Skills workshop at the SheBelieves Summit, which underscores the importance of financial literacy and how to plan ahead for financial success.
- The Second Half: Inspired by Visa’s groundbreaking partnership with UEFA Women’s Football and the FIFA Women’s World CupTM , Visa recently announced the launch of The Second Half ; a career development program to support female footballers in Europe, as they consider their careers beyond the football pitch.
- Olympic and Paralympic Games: Visa’s sponsored athlete program of Olympic and Paralympic hopefuls, Team Visa, has been comprised of more than 50% women athletes looking back historically at the full roster. For Tokyo 2020, Visa is supporting more than 50 female Olympic and Paralympic hopefuls from around the world. Additionally, in the lead up to the Olympic Winter Games Beijing 2022 - Visa, the China Women’s Development Foundation and Beijing Sport University announced a program aimed to empower women to grow their small businesses and contribute to local social-economic development and sustainable growth.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device, for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , visa.com/blog and @VisaNews .
1
Gem 2016/2017 Women's Entrepreneurship Report
2
Gem 2018/2019 Women's Entrepreneurship Report
3
International Monetary Fund’s Pursuing Women's Economic Empowerment
4
Visa 2020 State of Female Entrepreneurship Report, conducted by Logica Research on behalf of Visa to 400 adult, female small business owners in February 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
